Tirzepatide: Primary completion and completion of P3 SURMOUNT-MAINTAIN trial (NCT06047548) for the maintenance of body weight reduction in participants who have obesity or overweight with weight-related comorbidities in May 2026 (Eli Lilly) - Oct 30, 2024 - Q3 2024 Results: Primary and completion of P3 SURMOUNT-ADOLESCENTS trial (NCT06075667) in adolescent participants who have obesity or overweight with weight-related comorbidities in Oct 2026
Trial completion date • Trial primary completion date • Metabolic Disorders • Obesity
|